Please login to the form below

Not currently logged in

Pharma deals in August 2015

Medius Deal Watch

During a busy month AstraZeneca, Sanofi and Shire were among those hitting the headlines

Could EFPIA's new code boost pharma's reputation?

Rule changes for payments to doctors could present the industry with an opportunity

The death of the cancer drugs fund?

UK flagNHS England's siloed budget and its uncertain future

Biosimilars - the same, but different?

As more products reach European markets, US regulations are catching up with science

Pharma deals in July 2015

Medius Deal WatchA hot summer month for industry M&A, finds Medius Deal Watch

The Gallery

A visual showcase of agency work. Track down an agency from the image, track down your competitors' work, search by product or therapy area to pull up, for example, cardiovascular campaigns. Click here for a portfolio of hundreds of campaign visuals – updated regularly – free for you to reference. Agencies – it's free to add your pharma/healthcare campaigns. Just contact us.


Drivers for change – payer value perceptions

In an ever-changing healthcare environment, the need to prove value for money remains a key focus for payers and reimbursement decision makers.

Patient engagement: the future for outcomes research and clinical trials?

There is growing momentum and recognition among researchers, regulatory agencies, policy makers and payers towards a more patient-centric approach to health outcomes research, including development and validation of Clinical Outcome

Sales reps in the digital age

As the number of doctors willing to see pharmaceutical sales representatives in person declines how digital tools can help with access, reach and rep effectiveness?

Next-generation KOL intelligence

Advances in KOL intelligence are delivering richer insights into clinical landscapes than ever before, better enabling pharma to meet the challenges of an increasingly competitive and complex environment for KOL

Country reports

The death of the cancer drugs fund?

UK flagNHS England's siloed budget and its uncertain future

Is obesity really a problem in Brazil?

Obesity is on the rise in low- and middle-income countries, particularly in urban settings

Turkey: A growing pharma market with huge potential

The Turkish biopharma market offers many opportunities - if it can overcome its sustainability challenge


The challenge of antimicrobial resistance

Cubist Patrick-Vink Cubist's Patrick Vink on the company's ambitions in anti-infectives

Switching to a virtual healthcare system

babylon virtual health service Ali Parsa, CEO and founder of babylon, discusses the benefits of conducting healthcare consultations via a smartphone

The role of artificial intelligence in healthcare

Watson on jeopardy IBM's Amer Fasihi on the rise of Watson

White papers

Organisational Memory

In a knowledge-based industry with high labour mobility, retaining that knowledge within an organisation during a drug’s lifecycle can be tricky. If we undervalue the knowledge, experience and marketing understanding

Thoughts on the intersection between technology and psychology

Paul Mannu - Master Practitioner, Behavioural Insights at Cello Health Insight gives us his succinct thoughts on the intersection between technology and psychology

Learning to listen - Examining the opportunities and challenges of using conversations on social media for Pharma brands

The world in which we do business has markedly changed since 2008, which has helped to increase the push towards the ‘digitisation’ of marketing communications’ channels, This feature explores the

#BleedForEngland and Become a Different Type of Hero

Justine Brodie on NHS's latest blood donation campaign

Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude

We are experts in customer engagement. A strategic multichannel marketing and customer experience consultancy. Our focus is creating exceptional customer...